For the Treatment of Multiple Myeloma Hematologist-Oncologists Consider the Performance of Velcade More Favorably than Rev

Celgene’s pomalidomide and Onyx Pharmaceuticals’ carfilzomib will bring the greatest value for the treatment of Multiple Myeloma compared with all profiled emerging therapies according to a new report by BioTrends Research Group

EXTON, Pa.--(BUSINESS WIRE)-- Current treatment options for Multiple Myeloma focus on the use of Takeda/Millennium/Janssen-Cilag’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and Celgene’s Thalomid (thalidomide). Competition between these agents is intense in all lines of treatment despite Revlimid lacking approval in the first-line setting. Use of Velcade and Revlimid in combination reduces this competition and such regimens are considered to be the most efficacious according to surveyed hematologist-oncologists.

The choice between Velcade and Revlimid depends on several factors, but Velcade is perceived to perform significantly better than both Revlimid and Thalomid with respect to overall efficacy (the most important clinical attribute) for the treatment of Multiple Myeloma according to surveyed hematologist-oncologists. In the first-line settings, the factors restricting Revlimid use include concerns over secondary malignancies, cost, and difficulties with stem-cell collection. However, hematologist-oncologists state that if Revlimid were approved in the first-line settings, the patient share of Revlimid would increase significantly and would offset both Thalomid and Velcade based regimens. Hematologists-oncologists report that the current unmet need for new therapies to treat Multiple Myeloma is significantly greater compared with most other hematology-oncology malignancies. Several emerging therapies are in development for the treatment of Multiple Myeloma, but hematologist-oncologists are mainly aware of only two – Onyx Pharmaceuticals’ carfilzomib and Celgene’s pomalidomide. Other emerging therapies (such as Bristol-Myers Squibb/Abbott’s elotuzumab), while less familiar to respondents, are considered to have highly attractive mechanisms of action for relapsed/refractory Multiple Myeloma.

TreatmentTrends®: Multiple Myeloma is a syndicated report, based on primary market research with 100 hematologist-oncologists, which provides a comprehensive view of the current and expected future management of Multiple Myeloma in the United States. The report covers analysis of Multiple Myeloma diagnosis, most important end points, and outcomes associated with Multiple Myeloma. The report includes patient shares of key therapies by line of treatment and the perception of these therapies in the treatment of Multiple Myeloma. The promotional messages of Velcade, Revlimid, and Thalomid are explored along with near-term expectations in prescribing practices, unmet medical need, analysis of the competitive landscape, and the most desirable product attributes.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com

All company, brand, or product names contained in this document may be trademarks of their respective holders.



CONTACT:

BioTrends Research Group, LLC
Elisa Ferrante, 610-321-9432
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Oncology  Pharmaceutical  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.